viewCytoDyn Inc.

CytoDyn presents 'stunning' data on treatment of HIV at Seattle conference

CytoDyn Inc (OTCQB:CYDY) CEO Dr. Nader Pourhassen and Dr. Richard Pestell tell Proactive Investors that Pourhassen presented data on its anti-HIV therapy at the Conference on Retroviruses and Opportunistic Infections in Seattle this week.

Highlights of the data include that patients had passed 12 weeks with close to 90% responders rate after the first induction period. And the company is ready to submit a pivotal trial to the FDA this month for final approval as a label expansion for mono-therapy.

Quick facts: CytoDyn Inc.

Price: 2.96 USD

Market: OTCQB
Market Cap: $1.43 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



Full interview: CytoDyn continues to report strong results from COVID-19...

CytoDyn Inc (OTCQB: CYDY) President and CEO Nader Pourhassan and Bruce Patterson, M.D. and Chief Executive Officer and founder of IncellDx joined Steve Darling from Proactive Vancouver with news the company continues to see more impressive results from COVID-19 patients who have received...

1 month, 1 day ago

2 min read